Merck Sues Xellia Over Plan For Generic Anti-Fungal Drug

Law360, New York (February 18, 2014, 4:39 PM EST) -- Merck Sharp & Dohme Corp. targeted drug manufacturer Xellia Pharmaceuticals ApS with a lawsuit in Delaware federal court on Friday, alleging that the generics company’s proposed version of the anti-fungal medication Cancidas will infringe on one of Merck’s patents.

At issue is U.S. Patent No. 5,952,300, which relates to compositions for treating and preventing fungal infections, according to the patent documents. Caspofungin acetate is the active ingredient in Cancidas. The complaint alleges that Xellia’s abbreviated new drug application for caspofungin acetate injectible in 50 mg and 70...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.